Return to Home

Altimmune, Inc.

ALT

Find Out if You Qualify for a Financial Reward by filling out the form below.

Lead Plaintiff Deadline:
July 05, 2024

Days Left:
-154

calendar

Altimmune, Inc. Form












Securities Fraud News does not share your information with others. There is no cost or obligation for you to submit.

Allegations

The filed complaint alleges that defendants made false statements and/or concealed that: (i) Altimmune overstated the potential for its lead product candidate, pemvidutide, to stand out from competing glucagon-like peptide-1 agonists based on the drug’s efficacy and tolerability results observed in the MOMENTUM Trial; (ii) accordingly, the MOMENTUM Trial results were less significant to pemvidutide’s clinical, commercial, and competitive prospects than Defendants had led investors to believe; (iii) as a result of all the foregoing, defendants had overstated Altimmune’s prospects for finding a strategic partner to develop pemvidutide; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of Altimmune purchased or acquired during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in Altimmune during the relevant time frame, you have until July 05, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Find More Cases

Ticker Symbol Company Name Join Deadline
UPS United Parcel Service, Inc. December 09, 2024 Join
EW Edwards Lifesciences Corporation December 13, 2024 Join
TD The Toronto-Dominion Bank December 23, 2024 Join
WOLF Wolfspeed, Inc. January 17, 2025 Join